Literature DB >> 28540890

Prevalence of osteoporosis in patients with chronic kidney disease (stages 3-5) in comparison with age- and sex-matched controls: A study from Kashmir Valley Tertiary Care Center.

M Saleem Najar1, Mohamad Muzzafer Mir1, Mudasir Muzamil1.   

Abstract

Chronic kidney disease (CKD) is associated with a range of metabolic bone diseases. Fracture rates are higher in CKD patients than age-matched controls throughout all the five stages of CKD. Dialysis patients have 4 times as many hip fractures as expected for their age. CKD forms an independent risk factor for osteoporosis, even in the absence of traditional risk factors. This study was carried out at the nephrology unit in a tertiary care center of Kashmir to know the prevalence of osteoporosis in CKD patients having glomerular filtration rate (GFR) <60 mL/min (stages 3-5). Among the 151 cases studied, the average estimated GFR was 16.78 ± 10.714 mL/min. There were 98 males (64.9%) and 53 females (35.1%). Their mean age was 51.01 ± 14.138 years. Osteoporosis based on femoral neck T-Score was seen in 31 patients (31.6%) while 43 patients (28.5%) had osteoporosis at L1, L2 lumbar vertebrae. The prevalence of osteoporosis based on femoral neck T-Score as well as osteopenia was highest in stage-5 CKD. In our study, the body mass index (BMI) had a positive correlation with osteoporosis; low BMI patients were at higher risk for osteoporosis (P = 0.014). In the Kashmir valley, the prevalence of osteoporosis was 31.8% in CKD patients against 22% in controls. Thus, CKD forms an important risk factor for osteoporosis even in the absence of traditional risk factors. We recommend early screening, detection, and management of osteoporosis to reduce the burden of morbidity and mortality in this subset of patients.

Entities:  

Mesh:

Year:  2017        PMID: 28540890     DOI: 10.4103/1319-2442.206439

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  10 in total

Review 1.  Secondary Osteoporosis and Metabolic Bone Diseases.

Authors:  Mahmoud M Sobh; Mohamed Abdalbary; Sherouk Elnagar; Eman Nagy; Nehal Elshabrawy; Mostafa Abdelsalam; Kamyar Asadipooya; Amr El-Husseini
Journal:  J Clin Med       Date:  2022-04-24       Impact factor: 4.964

2.  Causal Effects of Genetically Predicted Cystatin C on Osteoporosis: A Two-Sample Mendelian Randomization Study.

Authors:  Jiaqin Yuan; Lipeng Peng; Fujun Luan; Jie Li; Jinglin Zhang; Wei Jiang; Wenting Wang
Journal:  Front Genet       Date:  2022-05-02       Impact factor: 4.772

3.  Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Authors:  C Thongprayoon; P Acharya; C Acharya; J Chenbhanich; T Bathini; B Boonpheng; K Sharma; K Wijarnpreecha; P Ungprasert; M L Gonzalez Suarez; W Cheungpasitporn
Journal:  Osteoporos Int       Date:  2018-04-30       Impact factor: 4.507

4.  Bone density of the femoral neck in patients on maintenance dialysis.

Authors:  Kazushige Nakanishi; Kanji Shishido; Chiaki Kumata; Kae Ito; Yutaka Nakashima; Mikio Wakasa
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

5.  Chronic kidney disease can increase the risk of preoperative deep vein thrombosis in middle-aged and elderly patients with hip fractures.

Authors:  Zhen Wang; Ji Xiao; Zitao Zhang; Xusheng Qiu; Yixin Chen
Journal:  Clin Interv Aging       Date:  2018-09-11       Impact factor: 4.458

6.  Effect of long-term use of unfractionated or low-molecular-weight heparin on bone mineral density in maintenance hemodialysis patients.

Authors:  Shuo Yang; Qingyu Niu; Liangying Gan; Xiaobo Zhang; Lingxue Tu; Li Zuo
Journal:  Hemodial Int       Date:  2020-06-10       Impact factor: 1.812

7.  A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures.

Authors:  Lihua Xie; Xuantao Hu; Wenzhao Li; Zhengxiao Ouyang
Journal:  BMC Nephrol       Date:  2021-01-11       Impact factor: 2.388

8.  Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease.

Authors:  Ping-Hsun Wu; Ming-Yen Lin; Teng-Hui Huang; Tien-Ching Lee; Sung-Yen Lin; Chung-Hwan Chen; Mei-Chuan Kuo; Yi-Wen Chiu; Jer-Ming Chang; Shang-Jyh Hwang
Journal:  J Pers Med       Date:  2022-01-31

9.  Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.

Authors:  Chia-Yu Hsu; Li-Ru Chen; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

10.  Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark.

Authors:  M Sanni Ali; Martin Ernst; Danielle E Robinson; Fergus Caskey; Nigel K Arden; Yoav Ben-Shlomo; Mads Nybo; Katrine H Rubin; Andrew Judge; Cyrus Cooper; M K Javaid; Anne P Hermann; Daniel Prieto-Alhambra
Journal:  Arch Osteoporos       Date:  2020-06-01       Impact factor: 2.617

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.